Insmed Incorporated Given Average Rating of Buy by Analysts
INSM Stock | USD 70.53 0.06 0.09% |
About 55% of Insmed's investor base is interested to short. The analysis of the overall investor sentiment regarding Insmed Inc suggests that many traders are impartial. Insmed's investing sentiment overview a quick insight into current market opportunities from investing in Insmed Inc. Many technical investors use Insmed Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Insmed |
Insmed Incorporated has been given an average rating of Buy by the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last
Read at thelincolnianonline.com
Insmed Inc Current Investor Sentiment
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Insmed's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Insmed Inc.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Insmed Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Insmed can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Insmed Inc Historical Investor Sentiment
Investor biases related to Insmed's public news can be used to forecast risks associated with an investment in Insmed. The trend in average sentiment can be used to explain how an investor holding Insmed can time the market purely based on public headlines and social activities around Insmed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Insmed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Insmed and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Insmed news discussions. The higher the estimate score, the more favorable the investor's outlook on Insmed.
Insmed Fundamental Analysis
We analyze Insmed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Insmed is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Insmed Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Insmed stock to make a market-neutral strategy. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics with similar companies.
Peers
Insmed Related Equities
SWTX | SpringWorks Therapeutics | 5.00 | ||||
ASND | Ascendis Pharma | 2.43 | ||||
BGNE | BeiGene | 2.21 | ||||
HRMY | Harmony Biosciences | 1.95 | ||||
RVMD | Revolution Medicines | 1.05 | ||||
AKRO | Akero Therapeutics | 0.67 | ||||
HALO | Halozyme Therapeutics | 0.43 | ||||
APLS | Apellis Pharmaceuticals | 0.33 | ||||
BPMC | Blueprint Medicines | 0.21 | ||||
DAWN | Day One | 0.16 | ||||
RARE | Ultragenyx | 0.27 | ||||
FENC | Fennec Pharmaceuticals | 0.32 | ||||
RNA | Avidity Biosciences | 0.57 | ||||
JANX | Janux Therapeutics | 1.07 | ||||
EWTX | Edgewise Therapeutics | 1.20 | ||||
KROS | Keros Therapeutics | 2.39 | ||||
AGIO | Agios Pharm | 3.28 |
Check out Insmed Hype Analysis, Insmed Correlation and Insmed Performance. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.